Since 2004, CDG has completed three equity offerings raising in excess of $12 million, all in the form of common stock.
Additional equity investments are invited from venture capital firms and qualified individual investors to further fund operations through the anticipated Phase II clinical trial.
Current and prospective investors should direct inquiries to:
| Steven Fleck Chief Financial Officer CDG Therapeutics, Inc. 224-234-8515 |
David R. Volk Chief Executive Officer CDG Therapeutics, Inc. 312-301-8655 |